(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Cora Sternberg presented an analysis of the nature and manageability of adverse events (AEs) of ipatasertib and abiraterone within the context of the IPATential150 trial (NCT03072238) which compared this combination therapy to abiraterone along as a first-line treatment approach in metastatic castration resistant prostate cancer (mCRPC). To summarize the primary analyses which have been previously presented and published, the combination of ipatasertib and abiraterone significantly reduced the risk of disease worsening or death among patients with PTEN loss by immunohistochemistry (HR, 0.77; 95% CI: 0.61, 0.98; P = 0.034), but not among the entire intention to treat population.